Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. · 2019
Read Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. by Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6891890.txt.
Introduction
Huhn and co-authors compare schizophrenia drugs in The Lancet. Antipsychotics are the standard treatment for schizophrenia, one of the most burdensome mental illnesses. Dozens of agents exist, and which to choose first is contested. Trials usually test one drug against placebo or one rival, leaving the full field unranked.
The team ran a network meta-analysis, which links trials into one web of comparisons. It covered 32 oral antipsychotics from placebo-controlled and head-to-head randomised trials. Drugs were ranked on symptom relief and on side effects such as weight gain and sedation. All-cause dropout data covered 42,672 participants. Differences between agents were real but often modest, the authors found.
Catalog record
| CREATOR | Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis By Maximilian Huhn, Adriani Nikolakopoulou, Johannes Schneider-Thoma, Marc Krause, Myrto Samara, Natalie Peter, Thomas Arndt, Lio Bäckers, Philipp Rothe, Andrea Cipriani, John Davis, Georgia Salanti Published in: Lancet (London, England) DOI: 10.1016/S0140-6736(19)31135-3 ABSTRACT Summary Background Schizophrenia is one of the most common, burdensome, and costly psychiatric disorders in adults worldwide. Antipsychotic drugs are its treatment of choice, but there is controversy about which agent should be used. We aimed to compare and rank antipsychotics by quantifying information from randomised controlled trials. Methods We did a network meta-analysis of placebo-controlled and head-to-head randomised controlled trials and compared 32 antipsychotics. We searched Embase, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from database inception to Jan 8, 2019. Two authors independently selected studies and extracted data. We included randomised controlled trials in adults with acute symptoms of schizophrenia or related disorders. We excluded studies in patients with treatment resistance, first episode, predominant negative or depressive symptoms, concomitant medical illnesses, and relapse-prevention studies. Our primary outcome was change in overall symptoms measured with standardised rating scales. We also extracted data for eight efficacy and eight safety outcomes. Differences in the findings of the studies were explored in metaregressions and sensitivity analyses. Effect size measures were standardised mean differences, mean differences, or risk ratios with 95% credible intervals (CrIs). Confidence in the evidence was assessed using CINeMA (Confidence in Network Meta-Analysis). The study protocol is registered with PROSPERO, number CRD42014014919. Findings We identified 54 417 citations and included 402 studies with data for 53 463 participants. Effect size estimates suggested all antipsychotics reduced overall symptoms more than placebo (although not statistically significant for six drugs), with standardised mean differences ranging from −0·89 (95% CrI −1·08 to −0·71) for clozapine to −0·03 (−0·59 to 0·52) for levomepromazine (40 815 participants). Standardised mean differences compared with placebo for reduction of positive symptoms (31 179 participants) varied from −0·69 (95% CrI −0·86 to −0·52) for amisulpride to −0·17 (−0·31 to −0·04) for brexpiprazole, for negative symptoms (32 015 participants) from −0·62 (−0·84 to −0·39; clozapine) to −0·10 (−0·45 to 0·25; flupentixol), for depressive symptoms (19 683 participants) from −0·90 (−1·36 to −0·44; sulpiride) to 0·04 (−0·39 to 0·47; flupentixol). Risk ratios compared with placebo for all-cause discontinuation (42 672 participants) ranged from 0·52 (0·12 to 0·95; clopenthixol) to 1·15 (0·36 to 1·47; pimozide), for sedation (30 770 participants) from 0·92 (0·17 to 2·03; pimozide) to 10·20 (4·72 to 29·41; zuclopenthixol), for use of antiparkinson medication (24 911 participants) from 0·46 (0·19 to 0·88; clozapine) to 6·14 (4·81 to 6·55; pimozide). Mean differences compared to placebo for weight gain (28 317 participants) ranged from −0·16 kg (−0·73 to 0·40; ziprasidone) to 3·21 kg (2·10 to 4·31; zotepine), for prolactin elevation (21 569 participants) from −77·05 ng/mL (−120·23 to −33·54; clozapine) to 48·51 ng/mL (43·52 to 53·51; paliperidone) and for QTc prolongation (15 467 participants) from −2·21 ms (−4·54 to 0·15; lurasidone) to 23·90 ms (20·56 to 27·33; sertindole). Conclusions for the primary outcome did not substantially change after adjusting for possible effect moderators or in sensitivity analyses (eg, when excluding placebo-controlled studies). The confidence in evidence was often low or very low. Interpretation There are some efficacy differences between antipsychotics, but most of them are gradual rather than discrete. Differences in side-effects are more marked. These findings will aid clinicians in balancing risks versus benefits of those drugs available in their countries. They should consider the importance of each outcome, the patients' medical problems, and preferences. Funding German Ministry of Education and Research and National Institute for Health Research INTRODUCTION Schizophrenia is a common debilitating disorder (1% of the world population are afflicted) with a huge burden for patients, which cost the USA US$155·7 billion in 2013.1, 2 Antipsychotics are the mainstay of treatment,3 but are associated with important side-effects that can cause serious disability or death.4 According to WHO,5 many drugs are available that vary considerably in their affinity to different synaptic receptors, leading to possible diverging efficacy and safety profiles. Many guidelines recommend newer antipsychotics as the treatment of choice, but older antipsychotics are less costly and are still used worldwide, especially in low-income countries.6 Moreover, neither these older antipsychotics nor the more recently approved brexpiprazole and cariprazine have been compared in a comprehensive network meta-analysis.7 A clear understanding of the relative risks and benefits is essential for informed decision making. This systematic review and meta-analysis extends our previous work3 that combined evidence from 212 randomised trials on 15 antipsychotics and seven outcomes to 402 randomised trials on 32 antipsychotics and placebo and 17 efficacy and safety outcomes, with change in overall symptoms as the primary outcome. We aimed to better inform clinical practice and mental health policies by comparing all licensed second-generation and 17 first-generation antipsychotics in the acute treatment of adults with schizophrenia. Research in contextEvidence before this studyTreatment with antipsychotic drugs is the standard for the acute phase of schizophrenia according to most national and international guidelines. Nevertheless, antipsychotic use is debated strongly owing to side-effects and possible brain changes. Because many antipsychotic drugs are available, according to WHO, understanding how the many substances compare with each other is important, ideally ranked in a hierarchy. Due to their diverging receptor binding profiles, different antipsychotics can vary considerably in their efficacy and side-effect profiles. Even with a large evidence base of randomised clinical trials for acute treatment of schizophrenia, many evidence gaps remain, because many substances have never been compared directly in trials, especially older antipsychotics. We searched PubMed for network meta-analyses on the acute treatment of schizophrenic patients with antipsychotics published between database inception and Oct 5, 2018. Using the search terms “antipsychotic” AND “schizophrenia” AND (“network meta-analysis” OR “multiple treatment meta-analysis”), we found several relevant systematic reviews. Some examined specific subgroups, such as children or first-episode patients, whereas others were restricted to specific populations, such as Chinese or Japanese people. Some focused on special outcomes like weight gain or glucose. One network meta-analysis from 2013 did not include the newly approved antipsychotics cariprazine and brexpiprazole and examined only the two older antipsychotics haloperidol and chlorpromazine. Furthermore, not all clinically important efficacy and safety outcomes were studied in this report. Altogether we found no comprehensive and systematic network meta-analysis comparing older and newer antipsychotics for the acute treatment of schizophrenia over several efficacy and safety outcomes.Added value of this studyTo our knowledge, this analysis is the largest network meta-analysis done in the field of schizophrenia. It was based on 402 studies including 53 463 participants randomly assigned to 32 different older and newer antipsychotics or placebo. The addition of two new and 15 old antipsychotics is a major extension of a previous report by our group. We investigated ten additional important outcomes, such as specific aspects of efficacy, quality of life, and many more side-effects, and several methodological issues, such as placebo response and sample sizes. The primary outcome was reduction of overall schizophrenic symptoms, but we also examined other domains: reduction in positive and negative symptoms, dropouts, depression,